Michael D. Clayman - Jul 19, 2021 Form 4 Insider Report for Flexion Therapeutics Inc (FLXN)

Role
President and CEO, Director
Signature
/s/ Mark S. Levine, Attorney-in-Fact
Stock symbol
FLXN
Transactions as of
Jul 19, 2021
Transactions value $
$0
Form type
4
Date filed
7/20/2021, 08:44 PM
Previous filing
Jun 28, 2021
Next filing
Nov 19, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FLXN Common Stock Tax liability -13.9K -3.97% 335K Jul 19, 2021 Direct F1
holding FLXN Common Stock 374K Jul 19, 2021 By the Michael D.Clayman 2006 Revocable Trust
holding FLXN Common Stock 24.6K Jul 19, 2021 By the Michael D. Clayman Irrevocable Trust
holding FLXN Common Stock 389K Jul 19, 2021 By Versant Development Fund III, LLC F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Withholding of shares by the Issuer to satisfy income tax obligations associated with the vesting of a restricted stock unit award granted to the Reporting Person on July 16, 2020.
F2 Shares held by Versant Development Fund III, LLC. The Reporting Person is a manager and minority member of Versant Development Fund III, LLC. The Reporting Person disclaims any beneficial ownership of the shares held by Versant Development Fund III, LLC except to the extent of his pecuniary interest in these shares.